Core Viewpoint - The Schall Law Firm is investigating Telix Pharmaceuticals Limited for potential violations of securities laws related to misleading statements and undisclosed information regarding its prostate cancer therapeutic candidates [1][2]. Group 1: Investigation Details - The investigation centers on whether Telix issued false or misleading statements and failed to disclose relevant information to investors [2]. - On July 22, 2025, Telix announced it received a subpoena from the SEC concerning its disclosures about the development of its prostate cancer therapeutic candidates [2]. - Following the SEC subpoena announcement, Telix's American Depositary Receipts (ADRs) experienced a decline of over 10.4% the next day [2]. Group 2: Legal Representation - The Schall Law Firm is representing investors globally and specializes in securities class action lawsuits and shareholder rights litigation [3]. - Shareholders who have suffered losses are encouraged to contact the Schall Law Firm for a free discussion of their rights [3].
TLX Investors Have Opportunity to Join Telix Pharmaceuticals Limited Fraud Investigation with the Schall Law Firm